{"id":"placebo-for-ufh","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action. It is used as a control in clinical trials to compare the efficacy of active treatments.","oneSentence":"This drug has no known mechanism of action as it is a placebo.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:33.900Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT04545541","phase":"PHASE2, PHASE3","title":"Nebulised Heparin in Patients With Severe COVID-19","status":"COMPLETED","sponsor":"Australian National University","startDate":"2020-11-01","conditions":"Covid19, Respiratory Failure","enrollment":57},{"nctId":"NCT07214103","phase":"PHASE2","title":"Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-03-01","conditions":"Septic Shock, Coagulopathy","enrollment":120},{"nctId":"NCT04924322","phase":"PHASE2, PHASE3","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-05-11","conditions":"Deep Venous Thrombosis","enrollment":258},{"nctId":"NCT05204550","phase":"PHASE2, PHASE3","title":"Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-01-30","conditions":"COVID-19","enrollment":506},{"nctId":"NCT02974660","phase":"PHASE4","title":"Protamine Sulfate During Transcatheter Aortic Valve Implantation","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2016-12","conditions":"Aortic Valve Stenosis","enrollment":100},{"nctId":"NCT00064428","phase":"PHASE3","title":"OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Thromboembolism","enrollment":12092},{"nctId":"NCT02763839","phase":"PHASE1","title":"Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2001-04","conditions":"Parkinson's Disease","enrollment":19},{"nctId":"NCT02763852","phase":"PHASE1","title":"Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2001-04","conditions":"Parkinson's Disease","enrollment":18},{"nctId":"NCT01076764","phase":"PHASE3","title":"Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-04","conditions":"Acute Coronary Syndrome","enrollment":13220},{"nctId":"NCT01513200","phase":"PHASE1","title":"Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia","status":"COMPLETED","sponsor":"Stealth BioTherapeutics Inc.","startDate":"2012-01","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT00262054","phase":"PHASE4","title":"Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2005-11","conditions":"Coronary Disease, Angina Pectoris","enrollment":4570}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":131,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (for UFH)","genericName":"Placebo (for UFH)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug has no known mechanism of action as it is a placebo. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}